Eisai Establishes Operations in Korea
Tokyo (July 28, 1997) - Eisai Co., Ltd. of Tokyo (President and CEO:Haruo Naito) today announced the start of operations of Eisai Korea,Inc., a 100 percent Eisai subsidiariy, located in Seoul.
Eisai Korea, Inc. will begin preparations for clinical trials and marketing analyses for Eisai's products including an Alzheimer'sdisease treatment (E2020) and a proton pump inhibitor (E3810).
In May 1996, Eisai established a representative office to undertake marketing analyses of the pharmaceutical market. Eisai Korea, Inc. will now assume the responsibilities of the representative office.
Eisai first established operations in Asia in the 1960s and now has ten subsidaries located in the ASEAN countries, China, and Taiwan. Eisai Korea Inc. will establish Eisai's presence within the Korean heath care market.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of worldwide health care systems. The Company reported sales of $2.3 billion in 1996 with approximately 14 percent of sales spent on research and development.